These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 18270751)

  • 1. The effects of candesartan on diabetes glomerulopathy: a double-blind, placebo-controlled trial.
    Perrin NE; Jaremko GA; Berg UB
    Pediatr Nephrol; 2008 Jun; 23(6):947-54. PubMed ID: 18270751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
    Bilous R; Chaturvedi N; Sjølie AK; Fuller J; Klein R; Orchard T; Porta M; Parving HH
    Ann Intern Med; 2009 Jul; 151(1):11-20, W3-4. PubMed ID: 19451554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials.
    Chaturvedi N; Porta M; Klein R; Orchard T; Fuller J; Parving HH; Bilous R; Sjølie AK;
    Lancet; 2008 Oct; 372(9647):1394-402. PubMed ID: 18823656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial.
    Sjølie AK; Klein R; Porta M; Orchard T; Fuller J; Parving HH; Bilous R; Chaturvedi N;
    Lancet; 2008 Oct; 372(9647):1385-93. PubMed ID: 18823658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients with Mild to Moderate Essential Hypertension.
    Lee JH; Yang DH; Hwang JY; Hur SH; Cha TJ; Kim KS; Kim MH; Chun KJ; Cha GS; Hong GR; Lee SG; Kim DS; Kim DI; Chae SC
    Clin Ther; 2016 Jun; 38(6):1485-1497. PubMed ID: 27161546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Imarikiren in Patients with Type 2 Diabetes and Microalbuminuria: A Randomized, Controlled Trial.
    Ito S; Kagawa T; Saiki T; Shimizu K; Kuroda S; Sano Y; Umeda Y
    Clin J Am Soc Nephrol; 2019 Mar; 14(3):354-363. PubMed ID: 30755452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies.
    Luño J; Barrio V; Goicoechea MA; González C; de Vinuesa SG; Gómez F; Bernis C; Espinosa M; Ahijado F; Gómez J; Escalada P
    Kidney Int Suppl; 2002 Dec; (82):S47-52. PubMed ID: 12410855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The course of diabetic glomerulopathy in patients with type I diabetes: a 6-year follow-up with serial biopsies.
    Perrin NE; Torbjörnsdotter TB; Jaremko GA; Berg UB
    Kidney Int; 2006 Feb; 69(4):699-705. PubMed ID: 16518327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET.
    Philipp T; Martinez F; Geiger H; Moulin B; Mourad G; Schmieder R; Lièvre M; Heemann U; Legendre C
    Nephrol Dial Transplant; 2010 Mar; 25(3):967-76. PubMed ID: 19887503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicentre, 12-week study of imidapril and candesartan cilexetil in patients with mild to moderate hypertension using ambulatory blood pressure monitoring.
    Palma-Gamiz JL; Pêgo M; Marquez E; Pujol M; Olivan J; Alegría E; Sagastagoitia-Gorostiza JD; Gonzalez-Juanatey JR
    Clin Drug Investig; 2007; 27(6):407-17. PubMed ID: 17506591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility of treating prehypertension with an angiotensin-receptor blocker.
    Julius S; Nesbitt SD; Egan BM; Weber MA; Michelson EL; Kaciroti N; Black HR; Grimm RH; Messerli FH; Oparil S; Schork MA;
    N Engl J Med; 2006 Apr; 354(16):1685-97. PubMed ID: 16537662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ARTA: AT1-receptor blocker therapy in patients undergoing coronary artery bypass grafting.
    Flesch M; Knipp S; Kessler G; Geissler HJ; Massoudy P; Wilhelm H; Philipp T; Erdmann E
    Clin Res Cardiol; 2009 Jan; 98(1):33-43. PubMed ID: 18853093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients.
    Koh KK; Quon MJ; Han SH; Chung WJ; Ahn JY; Kim JA; Lee Y; Shin EK
    Diabetes Care; 2006 Feb; 29(2):195-201. PubMed ID: 16443859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus.
    Rosei EA; Rizzoni D; Muiesan ML; Sleiman I; Salvetti M; Monteduro C; Porteri E;
    J Hypertens; 2005 Feb; 23(2):435-44. PubMed ID: 15662233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Candesartan in the Acute Phase of Intracerebral Hemorrhage.
    Jusufovic M; Berge TE; Guo R; You S; Delcourt C; Anderson C; Bath PM; Karlson BW; Berge E; Sandset EC;
    J Stroke Cerebrovasc Dis; 2019 Aug; 28(8):2262-2267. PubMed ID: 31178359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy.
    Bönner G;
    Blood Press Suppl; 2008 Dec; 2():22-30. PubMed ID: 19203019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study.
    Lindhardt M; Persson F; Zürbig P; Stalmach A; Mischak H; de Zeeuw D; Lambers Heerspink H; Klein R; Orchard T; Porta M; Fuller J; Bilous R; Chaturvedi N; Parving HH; Rossing P
    Nephrol Dial Transplant; 2017 Nov; 32(11):1866-1873. PubMed ID: 27507891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex).
    Ogihara T; Ueshima K; Nakao K; Fukiyama K; Oba K; Yasuno S; Fujimoto A; Sato T; Matsuoka H; Saruta T;
    Hypertens Res; 2011 Dec; 34(12):1295-301. PubMed ID: 21833000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial.
    Lithell H; Hansson L; Skoog I; Elmfeldt D; Hofman A; Olofsson B; Trenkwalder P; Zanchetti A;
    J Hypertens; 2003 May; 21(5):875-86. PubMed ID: 12714861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial.
    Ogihara T; Nakao K; Fukui T; Fukiyama K; Ueshima K; Oba K; Sato T; Saruta T;
    Hypertension; 2008 Feb; 51(2):393-8. PubMed ID: 18172059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.